Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cobolimab · 2 trials · 13 indications
OS is defined as the time from the date of randomization to the date of death due to any cause.
OS is defined as the time from the date of randomization to the date of death due to any cause.
Confirmed ORR is defined as the proportion of participants who have achieved confirmed complete response (CR) or confirmed partial response (PR), evaluated using disease-specific tumor assessment criteria based on Investigator assessment
| Arm | Type | Description |
|---|---|---|
| Participants receiving cobolimab+ dostarlimab+ docetaxel | EXPERIMENTAL | - |
| Participants receiving dostarlimab+ docetaxel | EXPERIMENTAL | - |
| Participants receiving docetaxel | ACTIVE_COMPARATOR | - |
| Part 1- Dose determination | EXPERIMENTAL | - |
| Part 2- Dose expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cobolimab | BIOLOGICAL | Cobolimab will be administered. |
| Dostarlimab | BIOLOGICAL | Dostarlimab will be administered. |
| Docetaxel | DRUG | Docetaxel will be administered. |
Inclusion Criteria: * Participant has histologically or cytologically proven advanced or metastatic NSCLC and only squamous or non-squamous cell carcinoma. * Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum based (...
Cobolimab is an investigational monoclonal antibody being studied for use in oncology, specifically in non-small cell lung cancer, melanoma, and other cancers. It is currently in Phase 2 clinical development for advanced non-small cell lung cancer and Phase 1 for pediatric and young adult cancers.
Cobolimab is a monoclonal antibody, a type of -mab antibody. Its specific molecular target is not disclosed in available information. It is being studied in combination with other therapies for the treatment of various cancers.
Cobolimab is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of Cobolimab in multiple cancer indications.
Cobolimab is in Phase 2 clinical development for advanced non-small cell lung cancer. It is also being studied in a Phase 1 trial for pediatric and young adult cancers. Cobolimab is investigational and has not been approved by regulatory authorities.
Cobolimab is being evaluated in two active clinical trials. NCT04655976 is a Phase 2 study comparing Cobolimab plus dostarlimab and docetaxel to other combinations in advanced non-small cell lung cancer. NCT06521567 is a Phase 1 study of Cobolimab plus dostarlimab in pediatric and young adult cancer patients.
No, Cobolimab is not the same as dostarlimab. They are distinct investigational drugs being studied together in combination. In clinical trials, Cobolimab is combined with dostarlimab and docetaxel to evaluate its efficacy in treating advanced non-small cell lung cancer.